Literature DB >> 25913278

Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant.

Patrick Aouad1, Jamma Li2, Chris Arthur3, Richard Burt4, Suran Fernando5, John Parratt6.   

Abstract

We report a 47-year-old woman with highly active neuromyelitis optica (NMO) and persistent high titre anti-aquaporin-4 antibodies (anti-AQP-4) who was resistant to multiple immune therapies until she underwent autologous hematopoietic stem cell transplant (auto-HSCT). NMO is the only demyelinating disease with a clinically useful serum biomarker, aquaporin-4, a water channel protein expressed on astrocytes. Anti-AQP-4 antibodies correlate with NMO disease activity and animal models strongly suggest the antibody is pathogenic. Auto-HSCT was associated with clinical and radiological remission, improved disability and resolution of AQP-4 antibodies which are still undetectable 12 months later. The utility of auto-HSCT for refractory NMO warrants further investigation, particularly with regards to pre-conditioning regimens and the utility of AQP-4 antibodies as a biomarker for immunological and clinical remission.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Aquaporin-4; Autologous hematopoietic stem cell transplant; Neuromyelitis optica

Mesh:

Substances:

Year:  2015        PMID: 25913278     DOI: 10.1016/j.jocn.2015.02.007

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  9 in total

1.  Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD.

Authors:  Jiraporn Jitprapaikulsan; James P Fryer; Masoud Majed; Carin Y Smith; Sarah M Jenkins; Philippe Cabre; Shannon R Hinson; Brian G Weinshenker; Jay Mandrekar; John J Chen; Claudia F Lucchinetti; Yujuan Jiao; Jessica Segan; John E Schmeling; John Mills; Eoin P Flanagan; Andrew McKeon; Sean J Pittock
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-28

2.  Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge.

Authors:  Inês Furtado; Guiomar Pinheiro; Ana Campar; Teresa Mendonça
Journal:  BMJ Case Rep       Date:  2018-06-04

Review 3.  Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives.

Authors:  Giulia Ceglie; Laura Papetti; Massimiliano Valeriani; Pietro Merli
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

4.  Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).

Authors:  Basil Sharrack; Riccardo Saccardi; Tobias Alexander; Manuela Badoglio; Joachim Burman; Dominique Farge; Raffaella Greco; Helen Jessop; Majid Kazmi; Kirill Kirgizov; Myriam Labopin; Gianluigi Mancardi; Roland Martin; John Moore; Paolo A Muraro; Montserrat Rovira; Maria Pia Sormani; John A Snowden
Journal:  Bone Marrow Transplant       Date:  2019-09-26       Impact factor: 5.483

Review 5.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

Review 6.  Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Authors:  Giordani Rodrigues Dos Passos; Douglas Kazutoshi Sato; Jefferson Becker; Kazuo Fujihara
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

Review 7.  Autologous haematopoietic stem cell transplantation for neurological diseases.

Authors:  Joachim Burman; Andreas Tolf; Hans Hägglund; Håkan Askmark
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-09-02       Impact factor: 10.154

Review 8.  Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.

Authors:  Staley A Brod
Journal:  Mult Scler Relat Disord       Date:  2020-10-07       Impact factor: 4.339

Review 9.  Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.

Authors:  Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes; Kjell-Morten Myhr; Øivind Torkildsen
Journal:  J Neurol       Date:  2020-10-03       Impact factor: 6.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.